Literature DB >> 30120739

Comment on: "Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring".

Alain Braillon1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30120739     DOI： 10.1007/s40264-018-0714-7

Source DB:  PubMed          Journal:  Drug Saf        ISSN： 0114-5916            Impact factor:   5.606


× No keyword cloud information.
  11 in total

Review 1.  Meta-analyses with industry involvement are massively published and report no caveats for antidepressants.

Authors:  Shanil Ebrahim; Sheena Bance; Abha Athale; Cindy Malachowski; John P A Ioannidis
Journal:  J Clin Epidemiol       Date:  2015-09-21       Impact factor: 6.437

2.  Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences.

Authors:  Joanna Moncrieff; Irving Kirsch
Journal:  Contemp Clin Trials       Date:  2015-05-12       Impact factor: 2.226

3.  Antidepressants' black-box warning--10 years later.

Authors:  Richard A Friedman
Journal:  N Engl J Med       Date:  2014-10-30       Impact factor: 91.245

4.  QTc interval prolongation associated with citalopram overdose: a case report and literature review.

Authors:  G Catalano; M C Catalano; M A Epstein; P E Tsambiras
Journal:  Clin Neuropharmacol       Date:  2001 May-Jun       Impact factor: 1.592

5.  The citalopram CIT-MD-18 pediatric depression trial: Deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance.

Authors:  Jon N Jureidini; Jay D Amsterdam; Leemon B McHenry
Journal:  Int J Risk Saf Med       Date:  2016-03-16

Review 6.  Comparative Benefits and Harms of Antidepressant, Psychological, Complementary, and Exercise Treatments for Major Depression: An Evidence Report for a Clinical Practice Guideline From the American College of Physicians.

Authors:  Gerald Gartlehner; Bradley N Gaynes; Halle R Amick; Gary N Asher; Laura C Morgan; Emmanuel Coker-Schwimmer; Catherine Forneris; Erin Boland; Linda J Lux; Susan Gaylord; Carla Bann; Christiane Barbara Pierl; Kathleen N Lohr
Journal:  Ann Intern Med       Date:  2015-12-08       Impact factor: 25.391

7.  Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: follow-up of the CoBalT randomised controlled trial.

Authors:  Nicola J Wiles; Laura Thomas; Nicholas Turner; Kirsty Garfield; Daphne Kounali; John Campbell; David Kessler; Willem Kuyken; Glyn Lewis; Jill Morrison; Chris Williams; Tim J Peters; Sandra Hollinghurst
Journal:  Lancet Psychiatry       Date:  2016-01-07       Impact factor: 27.083

8.  Selective publication of antidepressant trials and its influence on apparent efficacy.

Authors:  Erick H Turner; Annette M Matthews; Eftihia Linardatos; Robert A Tell; Robert Rosenthal
Journal:  N Engl J Med       Date:  2008-01-17       Impact factor: 91.245

Review 9.  Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review.

Authors:  R Kathryn McHugh; Sarah W Whitton; Andrew D Peckham; Jeffrey A Welge; Michael W Otto
Journal:  J Clin Psychiatry       Date:  2013-06       Impact factor: 4.384

10.  Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring.

Authors:  Mirjam Simoons; Adrie Seldenrijk; Hans Mulder; Tom Birkenhäger; Mascha Groothedde-Kuyvenhoven; Rob Kok; Cornelis Kramers; Wim Verbeeck; Mirjam Westra; Eric van Roon; Roberto Bakker; Henricus Ruhé
Journal:  Drug Saf       Date:  2018-07       Impact factor: 5.606
View more
  1 in total

1.  Authors' Response to Braillon's Comment on: "Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring".

Authors:  Mirjam Simoons; Adrie Seldenrijk; Hans Mulder; Eric van Roon; Roberto Bakker; Henricus Ruhé
Journal:  Drug Saf       Date:  2018-12       Impact factor: 5.606
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.